

**The difficult-to-control spread of carbapenemase producers in
Enterobacteriaceae worldwide**

Patrice Nordmann^{1,2,3*} and Laurent Poirel^{1,3}

¹Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, ²Hôpital Fribourgeois – Hôpital Cantonal de Fribourg, Fribourg, Switzerland, and ³INSERM U914, South-Paris Medical School, K.-Bicêtre, France

*Corresponding author. Mailing address: Medical and Molecular Microbiology Unit, □Department of Medicine, □Faculty of Science, □University of Fribourg, □rue Albert Gockel 3, □CH-1700 Fribourg, Switzerland. Phone: 41-26-300-9581. E-mail: patrice.nordmann@unifr.ch

Spread of carbapenemase producers in Enterobacteriaceae is now identified worldwide.

Three main carbapenemases are reported which belong to three classes of β -lactamases

that are KPC, NDM and OXA-48. The main reservoirs of KPC are Klebsiella pneumoniae

in the USA, Israel, Greece and Italy, of NDM are K. pneumoniae and Escherichia coli in

the Indian subcontinent, and of OXA-48 are K. pneumoniae and E. coli in North Africa

and Turkey. KPC producers remain mostly identified in nosocomial isolates whereas NDM and OXA-48 producers are both nosocomial and community-acquired pathogens. Control of their spread is still possible in hospital settings and relies on the use of rapid diagnostic techniques and strict implementation of hygiene measures.

Although rarely reported a decade ago, carbapenemase-producers in *Enterobacteriaceae*, they are extensively reported nowadays. Different groups of enzymes possessing carbapenemase properties have emerged, and are spreading worldwide concomitantly. Some of those enzymes hydrolyze carbapenems very efficiently whereas others exhibit weak activity against carbapenems. Some include broad-spectrum cephalosporins in their hydrolytic pattern, some do not. Some have an activity that may be inhibited (at least partially) by β -lactamase inhibitors (such as clavulanic acid, tazobactam) whereas most are not inhibited by clinically-available inhibitors. However, those significant differences do not really explain the success of the spread of specific enzymes in specific countries or areas [1].

The main features related to the epidemiology of those enzymes are as follows;

i) The first parameter is the primary reservoir. Indeed it is very likely that a specific enzyme emerges in a given geographical area where many favorable conditions exist such as high-density population, poor hygiene, high selective pressure linked to over- and misuse of antibiotics.

ii) The second parameter corresponds to the genetics of the carbapenemase gene, since some genetic structures are prone to enhance gene plasticity and mobility. Some integron or transposon structures and plasmids may indeed favorize horizontal gene transfer. Some plasmids possess broad-host range of replication, and can therefore enhance the inter-species dissemination, while some others possess narrow-host range. Some plasmids replicate very efficiently and are self-conjugative, while others are not self-conjugative or conjugate at very low rate. The genetic background of the strain harbouring the carbapenemase gene may also play an important role, since the emergence of one gene in a so-called successful clone (being for instances more prompt to disseminate from patient to patient, or more prompt to resist on dry surfaces) can favorize the initial spread of a carbapenemase through the spread of the corresponding bacterial host.

iii) The third main parameter corresponds to the level of human population exchanges once a reservoir is constituted. If the emergence of a carbapenemase occurs in a geographical area where the population is mobile (an important worldwide-located diaspora, tourism, medical tourism), then the likelihood to see that resistance determinant emerging worldwide is high.

The spread of carbapenemase genes are explained by those three parameters which are combined. Among the four molecular classes according to Ambler classification [2], carbapenemases can be found in classes A, B, and D.

The class A carbapenem-hydrolyzing β -lactamases

The first carbapenemase (NmcA, Non metallo-carbapenemase of class A) had been identified more than 20 years ago in an *Enterobacter cloacae* isolate. Then the SME enzymes (*Serratia marcescens* enzyme) have been identified in *S. marcescens*. This family includes 5 variants (SME-1 to -5), all being chromosomally-encoded [3] and recovered sporadically throughout the United States and Canada [4-6, M. Mulvey, unpublished]. The IMI enzymes (IMIpenem-hydrolyzing β -lactamase) have been detected in rare isolates of *Enterobacter* spp. in USA [7], France [8], Croatia [9], Finland [10] and Argentina[11], and more recently a colistin-resistant

Enterobacter asburiae isolate was recovered in Ireland [12]. The genes encoding those carbapenemases are mostly chromosomally-located and associated to an AmpC type regulation (LysR dependant), thus limiting their spread and their expression at a high level. However, genes encoding the IMI-2 variant have been found plasmid-located in environmental *Enterobacter asburiae* strains recovered from several US rivers [13] and in a single *E. cloacae* isolate in China [14].

The first variant of the GES family (for “Guiana Extended-Spectrum β -lactamase”) which is GES-1 which is not a carbapenemase was reported in 2000. The GES family now includes 24 variants (<http://www.lahey.org/Studies/other.asp#table1>) [15]. All the GES variants possess the ability to hydrolyze broad-spectrum cephalosporins, but through specific amino acid substitutions inside the active site, the extension of their spectrum of activity towards carbapenems has been identified for several variants [16]. Among these variants, the GES-2, -4, -5, -6, -11, -14, and -18 hydrolyze imipenem efficiently [17]. Although quite rare, GES enzymes have been identified worldwide. Among those GES variants for which a significant carbapenemase activity is noticed, there are; GES-2 identified in *Pseudomonas aeruginosa*, with one clone being the source of a nosocomial outbreak in South Africa [18];

GES-5 identified in *Enterobacteriaceae* and *P. aeruginosa*, being widely reported in South America (Brazil) [19,20], and some scattered reports in Turkey [21] and South Korea [22]. The GES-11 and -14 variants have been identified in *Acinetobacter baumannii* only [23], and GES-18 identified in *P. aeruginosa* and not in *Enterobacteriaceae* [24].

Noteworthy, this GES-5 variant possessing a significant carbapenemase activity has disseminated quite widely, being found not only in nosocomial settings but also in the environment in South America [25], and being the main carbapenem-hydrolyzing GES-type enzyme to be identified in *Enterobacteriaceae*. The high rate of GES-5 producers in South America and in particular in Brazil [26] might be a consequence of the occurrence of the non-carbapenemase GES-1 variant in the same geographical area [27]. It might be speculated that a selective pressure with carbapenems selected GES-5 along the years is at the origin of the emergence of that carbapenemase.

KPC enzymes (*Klebsiella pneumoniae* carbapenemases) are currently the most clinically-significant enzymes among the class A carbapenemases. Indeed, they are mainly identified in *K. pneumoniae* which is an important nosocomial pathogen, and confer high

level of resistance not only to carbapenems but also to most β -lactams including broad-spectrum cephalosporins. The first KPC producer (a KPC-2-positive *K. pneumoniae*) was identified in 1996 in the Eastern coast of the USA [28] and then a series of variants have been identified, even though KPC-2 remains the most commonly identified variant. There are now nineteen KPC variants assigned, all being point-mutant derivatives of a common amino acid sequence. Within a few years, KPC producers went global and identified in many Gram negative species even though KPC enzymes are mostly identified in *K. pneumoniae* [29]. In Latin America, KPC producers are endemic in some areas, such as in Colombia, and Argentina [29]. Some reports also showed the occurrence of KPC producers in Puerto Rico and Mexico [30,31].

In Europe, KPC producers have been found almost everywhere, most of the time being linked to imports from endemic areas [29]. Those endemic areas in Europe are Greece and Italy, and probably Poland where nosocomial outbreaks due to KPC-producing *K. pneumoniae* often occur [32]. In Israel the endemicity of KPC producers has been demonstrated through many studies, with lots of nosocomial reports but also, noticeably, with some community-occurring cases [29,33].

The extent of the diffusion of KPC in South East Asia is not well known, even if China is considered as a country where some areas are facing out endemic situations [29]. In India, very few reports on KPC-producing isolates do exist, the most commonly identified carbapenemases being NDM and OXA-48-like enzymes (see below). However there are some reports showing that KPC producers are occurring in India [34,35].

Noteworthy, one specific KPC-2- or KPC-3-producing *K. pneumoniae* clone (ST258) has been extensively identified worldwide [36], indicating that it has significantly contributed to the spread of this resistance trait.

The class B metallo β -lactamases (MBL)

MBLs which are known to be intrinsic in many environmental and opportunistic bacterial species have been identified as acquired enzymes since the early 1990's, either in *Pseudomonas* or in *Enterobacteriaceae* [37]. The most common families of acquired class B MBLs identified in *Enterobacteriaceae* include the VIM- and IMP- groups [37], together with the emerging NDM group (see below), whereas others such as GIM-1 and KHM-1 are sporadic [38,39]. Although reported worldwide, the VIM producers in *Enterobacteriaceae* are

highly prevalent in Southern part of Europe and around the Mediterranean sea (first reported in Italy by Cornaglia and colleagues) whereas the IMP producers remain mostly located in Asia [37].

IMP-type β -lactamases have been the first acquired MBLs to be identified and detected in a series of clinically important Gram-negative bacilli, such as in *Enterobacteriaceae*, *Pseudomonas* spp., *Acinetobacter* spp.. In *Enterobacteriaceae*, IMP-1 was reported from a *Serratia marcescens* isolate in Japan in 1991 [40]. So far, 48 IMP variants have been assigned and IMP-type carbapenemase producers have spread worldwide. However the occurrence of IMP-producing isolates worldwide is much less than that of KPC-, VIM-, NDM-, or OXA-48 producers. Wide spread of IMP-type enzymes has been demonstrated mainly in Japan, Taiwan, and Eastern China, although single reports have been reported in many other countries, being sometimes at the origin of nosocomial outbreaks. Another type of MBL corresponds to the VIM-type enzymes (Verona Integron-encoded Metallo- β -lactamase). VIM-1 was first identified in Italy in 1997 [41,42] and then the VIM-2 variant was reported in France from a *P. aeruginosa* isolate dating from 1996 [43]. Currently, the VIM family includes 41 variants, mainly identified from *P. aeruginosa* but also from

enterobacterial isolates. VIM-2 is actually the most reported MBL worldwide [1], with an endemic spread in Southern Europe (Greece, Spain, Italy) and Southeast Asia (South Korea, Taiwan), but also found as causing outbreaks in Africa, and in particular in the Ivory Coast [44], South Africa [45], Tunisia [46], or some European countries such as Germany [47], the Netherlands [48], and France [49,50]. Those outbreaks are most of the time involving VIM-producing *P. aeruginosa*, and rarely enterobacterial species. In Europe, Greece is known to be an endemic place for VIM-1-producing Enterobacteriaceae. Many Greek studies report the spread of VIM-1-producing *K. pneumoniae* at a national scale, but this enzyme is also identified in *E. coli*, *Citrobacter freundii*, *Morganella morganii*, *Serratia* spp., and *Klebsiella oxytoca* [51,52].

Recently, the KHM-1 β -lactamase has been identified in Japan from a single *C. freundii* clinical isolate that had been recovered in 1997 [39]. The GIM-1 MBL (that stands for “German Imipenemase”) which has been firstly identified from a *P. aeruginosa* isolate from Germany [38] has been then identified in other *P. aeruginosa* isolates [53] but also in *Serratia marcescens* [54], *Enterobacter cloacae* [55] and *Acinetobacter pittii* [56]. Worryingly, it was recently shown that GIM-1 was identified in many enterobacterial species, including *E.*

coli, *C. freundii*, and *K. oxytoca*, always in Germany [53]. The other described acquired MBLs include SPM-1 [57], SIM-1 [58], DIM-1 [59], TMB-1 [60], and AIM-1 [61], but they have not been identified in *Enterobacteriaceae*, being either from *Pseudomonas* spp. or *Acinetobacter* spp

One of the most most clinically-significant carbapenemase is NDM-1 (New Delhi metallo- β -lactamase) described in 2009, the corresponding *K. pneumoniae* and *E. coli* isolates being from a Swedish patient of Indian origin hospitalized in Örebro, Sweden, after a hospital stay in New Delhi [62,63]. NDM-1 shares very little identity with other MBLs, the most similar being VIM-1/VIM-2 with only 32.4% amino acid identity. NDM-1 efficiently hydrolyses a broad range of β -lactams including penicillins, cephalosporins and carbapenems, just sparing monobactams such as aztreonam [62]. Since the first description of NDM-1, eight variants of this enzyme have been published (NDM-1 to -8) and twelve have been assigned (<http://www.lahey.org>), most of them originated from Asia [64-66]. Compared to NDM-1, the NDM-4, NDM-5 and NDM-7 variants possess increased activity towards carbapenems [67-70]. A detailed analysis of the resistance patterns show their systematic association with other antibiotic resistance determinants such as plasmid-mediated AmpC cephalosporinases,

clavulanic-acid inhibited expanded-spectrum β -lactamases (ESBLs), other types of carbapenemases (OXA-48-, VIM-, KPC-types), broad spectrum resistance to aminoglycosides (16S RNA methylases), to quinolones (Qnr), to macrolides (esterases), to rifampicin (rifampicin-modifying enzymes), to chloramphenicol and to sulfamethoxazole [71,72]. Consequently, many of the NDM-1 producers remain susceptible only to colistin, fosfomycin and tigecycline [73].

The main identified reservoir of NDM-producing *Enterobacteriaceae* is the Indian subcontinent (Pakistan, India, Sri Lanka) [63]. Spread of NDM producers has been not only extensively identified among patients from the Indian subcontinent but also from the soil [74,75]. Therefore, it is likely that there the environment is already heavily contaminated by NDM producers. The prevalence of carriage is estimated at 5 to 15 % in that part of the world [76,77]. A significant spread of NDM producers has been identified also in the Great Britain with tight relationships with India and Pakistan [65]. Subsequently, NDM producers in *Enterobacteriaceae* have been reported almost worldwide including many countries in Asia, Africa, Australia, America, and Europe [78]. NDM producers are now on the top list of carbapenemase producers in European countries such as in the UK and in France [63,65].

Another particularly important source of NDM producers (or established secondary reservoirs) is constituted by the Balkan states [79,80], the Arabic peninsula [81,82] and the North African countries [64]. The impact of intercontinental travels as a source of spread of NDM producers has been extensively reported. NDM producers are heavily identified in countries where many Indian and Pakistani live such as Canada, the USA, Great Britain, Ireland, South Africa, Saudi Arabia, Gulf countries, Australia etc... Noteworthy, the identification of NDM producers is not always associated with an Indian subcontinent origin, sustaining the hypothesis of established secondary reservoirs [83-87].

All types of NDM-producing enterobacterial species have been found involved in infections, but mostly *K. pneumoniae* and *E. coli* are sources of hospital and community acquired infections, respectively. The frequent identification of NDM-producing *E. coli* is of concern considering that *E. coli* is the first pathogen responsible for urinary tract infections, community-acquired infections, and diarrhea [88]. In fact, antibiotic resistance occurring in community settings are by definition very difficult to be contained and diarrhea is the source of a further spread of NDM producers in the environment at least in South East Asia.

It may therefore be expected that outbreaks due mostly to NDM-producing *K. pneumoniae* will be increasingly reported worldwide and concomitantly, a slow but progressive increase in the prevalence rate of NDM-producing *E. coli* will be observed, mirroring the spread of CTX-M producers we have observed in community settings since the 2000's. Noteworthy, outbreaks with NDM-1-producing *E. coli* or *E. cloacae* have been reported in Bulgaria and Turkey, respectively [89,90]. It is however difficult to evaluate the time (years) it will take to obtain similar prevalence rates of NDM-producing *E. coli* comparable to those observed for CTX-M producers (15-70% depending of the countries). Long-term persistence of NDM producers in the human gut will contribute to further human-to-human transfer [91], leading to some autochthonous cases in non endemic area as observed in France [92].

The carbapenem-hydrolysing class D β -lactamases

Class D β -lactamases, also named OXAs (for "oxacillinases") include now more than 400 enzymes, among which only some variants actually possess a carbapenemase activity [93]. With the exception of rare OXA-enzymes (such as OXA-163, see further), the carbapenem-hydrolysing class D β -lactamases (CHDLs) do not hydrolyse (or very poorly)

expanded-spectrum cephalosporins. Noticeably, all CHDLs possess a weak carbapenemase activity which, by itself, does not confer high level resistance to carbapenems if not associated to other factors, such as permeability defects [94].

Although most of the CHDLs variants have been identified in *Acinetobacter* spp., OXA-48 and its derivatives are identified in *Enterobacteriaceae* [95]. The firstly identified OXA-48 producer was a *K. pneumoniae* isolate recovered in Turkey in 2003 [96]. Then, OXA-48 producers have been extensively reported from Turkey, being often the sources of nosocomial outbreaks [96-99]. OXA-48-producing isolates have now widely disseminated throughout European countries, and it is highly probable that one of the main reservoir, apart from Turkey, corresponds to North African countries [95]. Indeed most countries from the Mediterranean area frequently report the occurrence of the OXA-48-producing *Enterobacteriaceae* [95]. Hospital outbreaks involving OXA-48-producing *K. pneumoniae*, *E. coli*, and *E. cloacae* have been reported in many countries including France, Germany, Switzerland, Spain, the Netherlands, and UK [100-105]. One of the main factors sustaining the successful spread of the *bla*_{OXA-48} gene among a variety of enterobacterial species corresponds to the high transfer efficiency of the plasmid on which *bla*_{OXA-48} is located [106].

That self-conjugative plasmid, which is considered as epidemic, does not carry any additional resistance determinant, and conjugates at very high frequency from an to any enterobacterial species [107].

OXA-48-producing isolates have been reported in the Middle East, such as in Lebanon, Sultanate of Oman, Saudi Arabia, and Kuwait [108-114]. In Africa, they are mainly identified in the Northern countries (Morocco, Algeria, Tunisia, Egypt, Libya) [115-127], but occurrence of OXA-48 producers has also been identified in Senegal and South Africa [128,129].

The same OXA-48-producing *K. pneumoniae* of sequence type (ST) ST395 has been identified in Morocco, in France, and in the Netherlands, indicating a clonal dissemination in some instances [120]. Noteworthy, the recently identified occurrence of OXA-48 producers in Israel was demonstrated to be linked with medical tourism, that involved patients who had been transferred from Georgia or in Jordania [130]. Also noticeable is the fact that OXA-48 is still considered almost absent from the Americas, even though recent reports showed the emergence of OXA-48-producing *K. pneumoniae* in the US [30].

A point-mutant derivative of OXA-48, namely OXA-181, sharing the same hydrolytic properties, has been identified in enterobacterial isolates from India or from patients with a link with the Indian subcontinent [131]. The genetic structure surrounding the *bla*_{OXA-181} gene was found to be distinct from that associated to *bla*_{OXA-48}, thus indicating their respective current disseminations are not related to each other. The *bla*_{OXA-181} gene has been identified in different countries such as France, UK, Norway, Romania, Sultanate of Oman, Canada, Australia, New Zealand, Singapore, and Sri Lanka, and a link with India is quite systematically observed [95,129,133].

OXA-204 was recently identified from a series of *K. pneumoniae* isolates recovered from patients having a link with Algeria or Tunisia. OXA-204 exhibits two amino acid substitutions compared to OXA-48, and preliminary data indicate a substrate profile very similar to that of OXA-48 [134] (Figure 2). OXA-232 has been recently identified from *K. pneumoniae* isolates in France, from patients who had been transferred from Mauritius or India [134]. It exhibits five amino acid substitutions compared to OXA-48, but is just a point mutant derivative of OXA-181. OXA-232 possesses a weaker ability to hydrolyze carbapenems as compared to OXA-48, but was recently found co-associated to NDM-1 in a

carbapenem-resistant *K. pneumoniae* isolate in the US very recently from a patient who had been previously identified in India [135].

Finally, another OXA-48-like enzyme, namely OXA-163, has been recently identified from enterobacterial isolates recovered in Argentina [136]. OXA-163 differs from OXA-48 by a single amino acid substitution together with a four amino-acid deletion [95,136]. Interestingly, although its carbapenemase activity is lower than that of OXA-48, its substrate profile includes broad-spectrum cephalosporins and its activity is partially inhibited by clavulanic acid, thus conferring to the corresponding enterobacterial recipient strains an resistance phenotype very similar to that of an ESBL producer. OXA-163 was originally identified from enterobacterial isolates (*E. cloacae* and *K. pneumoniae*) recovered in Argentina [136], and then in Egypt [137]. Other studies confirmed that OXA-163 producers were frequently identified in Argentina [30], and one single amino acid mutant (OXA-247) sharing the same hydrolytic properties was identified in that country [138].

Conclusion

Although the spread of carbapenemases appear to be quite recent, the “big players” which are NDM, KPC, and OXA-48 are widely distributed worldwide nowadays. Important reservoirs have been identified, being the Indian subcontinent for NDM, the US, Israel, Greece and Italy for KPC, and Turkey and North Africa for OXA-48. The Indian subcontinent actually acts as a reservoir of all three types of carbapenemases, KPC, NDM and OXA-181. KPC producers are still mostly identified in nosocomial *K. pneumoniae* isolates. By contrast NDM and OXA-48 enzymes are extensively identified in nosocomial and community-acquired *K. pneumoniae* and *E. coli* isolates, respectively. Interestingly KPC and NDM have been identified in unrelated Gram negatives species whereas OXA-48 remains identified only in enterobacterial species. However genetic analysis indicates that the OXA-48 gene will has a propensity to spread among enterobacterial species at a much higher rate than KPC and NDM genes.

The identified important reservoirs of those carbapenemase producers significantly act as sources for their dissemination worldwide. Indeed, it is extremely frequent to see that occurrence of a carbapenemase-producing isolate in a geographical area where there is no

endemicity or an epidemic situation linked to a patient who had a previous history of hospitalization or a travel in an endemic area. This indicates that a very early identification of carbapenemase producers at least in hospital settings may contribute to the limitation of their spread. Use of rapid diagnostic techniques is the key issue for their diagnosis followed by implementation of strict hygiene measure to limit their spread.

Legends to Figures.

Figure 1. Geographical distribution of KPC producers.

Figure 2. Geographical distribution of NDM producers.

Figure 3. Geographical distribution of OXA-48-like producers.

References

1. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. *Future Microbiol.* 2007; 2: 501-512.
2. Ambler RP, Coulson AF, Frère JM *et al.* A standard numbering scheme for the class A β -lactamases. *Biochem J* 1991; 276: 269-270.
3. Naas T, Vandell L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A β -lactamase, Sme-1, from

Serratia marcescens S6. *Antimicrob Agents Chemother* 1994; 38: 1262-1270.

4. Fairfax MR, Queenan AM, Lephart PR *et al.* Detection of two SME-1 carbapenemase-producing *Serratia marcescens* in Detroit. *Diagn Microbiol Infect Dis* 2011; 71: 325-326.
5. Queenan AM, Shang W, Schreckenberger P, Lolans K, Bush K, Quinn J. SME-3, a novel member of the *Serratia marcescens* SME family of carbapenem-hydrolyzing β -lactamases. *Antimicrob. Agents Chemother* 2006; 50: 3485-3487.
6. Naas T, Nordmann P. Analysis of a carbapenem-hydrolyzing class A β -lactamase from *Enterobacter cloacae* and of its LysR-type regulatory protein. *Proc Natl Acad Sci USA* 1994; 91: 7693-7697.
7. Rasmussen BA, Bush K, Keeney D *et al.* Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from *Enterobacter cloacae*. *Antimicrob Agents Chemother* 1996; 40: 2080-2086.
8. Naas T, Cattoen C, Bernusset S, Cuzon G, Nordmann P. First identification of *bla*_{IMI-1} in an *Enterobacter cloacae* clinical isolate from France. *Antimicrob Agents Chemother* 2012; 56: 1664-1665.
9. Bejuk D, Novkoski M, Juranko V *et al.* [A report of rarely observed resistance pattern

to carbapenems in a clinical isolate of *Enterobacter cloacae*]. *Lijec Vjesn* 2013; 135: 316-321.

10. Österblad M, Kirveskari J, Hakanen AJ, Tissari P, Vaara M, Jalava J. Carbapenemase-producing *Enterobacteriaceae* in Finland: the first years (2008-11). *J Antimicrob Chemother* 2012; 67: 2860-2864.

11. Radice M, Power P, Gutkind G *et al.* First class A carbapenemase isolated from *Enterobacteriaceae* in Argentina. *Antimicrob. Agents Chemother* 2004; 48: 1068-1069.

12. Boo TW, O'Connell N, Power L *et al.* First report of IMI-1-producing colistin-resistant *Enterobacter* clinical isolate in Ireland, March 2013. *Euro Surveill* 2013 Aug 1;18(31).

13. Aubron C, Poirel L, Ash JR, Nordmann P. Carbapenemase-producing *Enterobacteriaceae*, U.S. rivers. *Emerg Infect Dis* 2005; 11: 260-264.

14. Yu YS, Du XX, Zhou ZH, Chen YG, Li LJ. First isolation of *bla*_{IMI-2} in an *Enterobacter cloacae* clinical isolate from China. *Antimicrob Agents Chemother* 2006; 50: 1610-1611.

15. Poirel, L., Le Thomas I, Naas T, Karim A, Nordmann P. Biochemical sequence

analyses of GES-1, a novel class A extended-spectrum β -lactamase, and the class 1 integron In52 from *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2000; 44: 622-632.

16. Naas T, Poirel L, Nordmann P. Minor extended-spectrum β -lactamases. *Clin Microbiol Infect* 2008; 14 Suppl 1: 42-52.

17. Poirel L, Weldhagen GF, Naas T, De Champs C, Dove MG, Nordmann P. GES-2, a class A β -lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. *Antimicrob Agents Chemother* 2001; 45: 2598-2603.

18. Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of *Pseudomonas aeruginosa* isolates expressing the extended-spectrum β -lactamase GES-2 in South Africa. *J Antimicrob Chemother* 2002; 49: 561-565.

19. Ribeiro VB, Falci DR, Rozales FP, Barth AL, Zavascki AP. Carbapenem-resistant GES-5-producing *Klebsiella pneumoniae* in Southern Brazil. *Braz J Infect Dis* 2014; 18: 231-232.

20. Ribeiro VB, Zavascki AP, Rozales FP *et al*. Detection of *bla*_{GES-5} in carbapenem-resistant *Kluyvera intermedia* isolates recovered from the hospital environment. *Antimicrob Agents Chemother* 2014; 58: 622-623.

21. Iraz M, Duzgun AO, Cicek AC *et al.* Characterization of novel VIM carbapenemase, VIM-38, and first detection of GES-5 carbapenem-hydrolyzing β -lactamases in *Pseudomonas aeruginosa* in Turkey. *Diagn Microbiol Infect Dis* 2014; 78: 292-294.
22. Kim J, Hong SG, Bae IK *et al.* Emergence of *Escherichia coli* sequence type ST131 carrying both the *bla*_{GES-5} and *bla*_{CTX-M-15} genes. *Antimicrob Agents Chemother* 2011; 55: 2974-2975.
23. Bonnin RA, Nordmann P, Potron A, Lecuyer H, Zahar JR, Poirel L. Carbapenem-hydrolyzing GES-type extended-spectrum β -lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2011; 55: 349-354.
24. Bebrone C, Bogaerts P, Delbrück H *et al.* GES-18, a new carbapenem-hydrolyzing GES-Type β -lactamase from *Pseudomonas aeruginosa* that contains Ile80 and Ser170 residues. *Antimicrob Agents Chemother* 2013; 57: 396-401.
25. Manageiro V, Ferreira E, Caniça M, Manaia CM. GES-5 among the β -lactamases detected in ubiquitous bacteria isolated from aquatic environment samples. *FEMS Microbiol Lett* 2013 Nov 23. In press.
26. Polotto M, Casella T, de Lucca Oliveira MG *et al.* Detection of *Pseudomonas aeruginosa* harboring *bla*_{CTX-M-2}, *bla*_{GES-1} and *bla*_{GES-5}, *bla*_{IMP-1} and *bla*_{SPM-1} causing

infections in Brazilian tertiary-care hospital. *BMC Infect Dis* 2012; 12: 176.

27. Castanheira M, Mendes RE, Walsh TR, Gales AC, Jones RN. Emergence of the extended-spectrum β -lactamase GES-1 in a *Pseudomonas aeruginosa* strain from Brazil: report from the SENTRY antimicrobial surveillance program. *Antimicrob Agents Chemother* 2004; 48: 2344-2345.
28. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing β -lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2001; 45: 1151-1161.
29. Munoz-Price LS, Poirel L, Bonomo RA *et al.* Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis* 2013; 13: 785-796.
30. Lascols C, Peirano G, Hackel M, Laupland KB, Pitout JD. Surveillance and molecular epidemiology of *Klebsiella pneumoniae* isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America. *Antimicrob Agents Chemother* 2013; 57: 130-136.
31. Rodríguez-Zulueta P, Silva-Sánchez J, Barrios H et al. First outbreak of KPC-3-producing *Klebsiella pneumoniae* (ST258) clinical isolates in a Mexican Medical

Center. *Antimicrob Agents Chemother* 2013; 57: 4086-4088.

32. Baraniak A, Grabowska A, Izdebski R *et al.* Molecular characteristics of KPC-producing *Enterobacteriaceae* at the early stage of their dissemination in Poland, 2008-2009. *Antimicrob Agents Chemother* 2011; 55: 5493-5499.

33. Nordmann P, Cuzon G, Naas T. The real threat of *Klebsiella pneumoniae* carbapenemase-producing bacteria. *Lancet Infect Dis* 2009; 9: 228-236.

34. Kumarasamy K, Kalyanasundaram A. Emergence of *Klebsiella pneumoniae* isolate co-producing NDM-1 with KPC-2 from India. *J Antimicrob Chemother* 2012; 67: 243-244.

35. Potron A, Poirel L, Verdavaine D, Nordmann P. Importation of KPC-2-producing *Escherichia coli* from India. *J Antimicrob Chemother* 2012; 67: 242-243.

36. Cuzon G, Naas T, Truong H *et al.* Worldwide diversity of *Klebsiella pneumoniae* that produce β -lactamase *bla*_{KPC-2} gene. *Emerg Infect Dis* 2010; 16: 1349-1356.

37. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo- β -lactamases: the quiet before the storm? *Clin Microbiol Rev* 2005; 18: 306-325.

38. Castanheira M, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a β -lactamase gene, *bla*_{GIM-1}, encoding a new subclass of metallo-

β-lactamase. *Antimicrob Agents Chemother* 2004; 48: 4654-4661.

39. Sekiguchi J, Morita K, Kitao T *et al.* KHM-1, a novel plasmid-mediated metallo-β-lactamase from a *Citrobacter freundii* clinical isolate. *Antimicrob Agents Chemother* 2008; 52: 4194-4197.

40. Ito H, Arakawa Y, Ohsuka S, Wacharotayankun R, Kato N, Ohta M. Plasmid-mediated dissemination of the metallo-β-lactamase gene *bla*_{IMP} among clinically isolated strains of *Serratia marcescens*. *Antimicrob. Agents Chemother* 1995; 39: 824-829.

41. Lauretti L, Riccio ML, Mazzariol A *et al.* Cloning and characterization of *bla*_{VIM}, a new integron-borne metallo-β-lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. *Antimicrob Agents Chemother* 1999; 43: 1584-1590.

42. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant *Pseudomonas aeruginosa* producing VIM-1, a novel transferable metallo-β-lactamase. *Clin Infect Dis* 2000; 31: 1119-1125.

43. Poirel L, Naas T, Nicolas D *et al.* Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a *Pseudomonas aeruginosa* clinical isolate in France. *Antimicrob Agents Chemother*

2000; 44: 891-897.

44. Jeannot K, Guessennd N, Fournier D, Müller E, Gbonon V, Plésiat P. Outbreak of metallo- β -lactamase VIM-2-positive strains of *Pseudomonas aeruginosa* in the Ivory Coast. *J Antimicrob Chemother* 2013; 68: 2952-2954.
45. Jacobson RK, Minenza N, Nicol M, Bamford C. VIM-2 metallo- β -lactamase-producing *Pseudomonas aeruginosa* causing an outbreak in South Africa. *J Antimicrob Chemother* 2012; 67: 1797-1798.
46. Hammami S, Boutiba-Ben Boubaker I, Ghazzi R, Saidani M, Amine S, Ben Redjeb S. Nosocomial outbreak of imipenem-resistant *Pseudomonas aeruginosa* producing VIM-2 metallo- β -lactamase in a kidney transplantation unit. *Diagn Pathol* 2011; 6: 106.
47. Elias J, Schoen C, Heinze G *et al.* Nosocomial outbreak of VIM-2 metallo- β -lactamase-producing *Pseudomonas aeruginosa* associated with retrograde urography. *Clin Microbiol Infect* 2010; 16: 1494-1500.
48. Van der Bij AK, Van Mansfeld R, Peirano G *et al.* First outbreak of VIM-2 metallo- β -lactamase-producing *Pseudomonas aeruginosa* in The Netherlands: microbiology, epidemiology and clinical outcomes. *Int J Antimicrob Agents* 2011; 37: 513-518.

49. Corvec S, Poirel L, Espaze E, Giraudeau C, Drugeon H, Nordmann P. Long-term evolution of a nosocomial outbreak of *Pseudomonas aeruginosa* producing VIM-2 metallo-enzyme. *J Hosp Infect* 2008; 68: 73-82.
50. Kassis-Chikhani N, Decré D, Gautier V *et al.* First outbreak of multidrug-resistant *Klebsiella pneumoniae* carrying *bla*_{VIM-1} and *bla*_{SHV-5} in a French university hospital. *J Antimicrob Chemother* 2006; 57: 142-145.
51. Miriagou V, Douzinas EE, Papagiannitsis CC, Piperaki E, Legakis NJ, Tzouveleki LS. Emergence of *Serratia liquefaciens* and *Klebsiella oxytoca* with metallo- β -lactamase-encoding IncW plasmids: further spread of the *bla*_{VIM-1}-carrying integron In-e541. *Int J Antimicrob Agents* 2008; 32: 540-541.
52. Psychogiou M, Tassios PT, Avlami A *et al.* Ongoing epidemic of *bla*_{VIM-1}-positive *Klebsiella pneumoniae* in Athens, Greece: a prospective survey. *J Antimicrob Chemother* 2008; 61: 59-63.
53. Wendel AF, Brodner AH, Wydra S *et al.* Genetic characterization and emergence of the metallo- β -lactamase GIM-1 in *Pseudomonas* spp. and *Enterobacteriaceae* during a long-term outbreak. *Antimicrob Agents Chemother* 2013; 57: 5162-5165.
54. Rieber H, Frontzek A, Pfeifer Y. Emergence of metallo- β -lactamase GIM-1 in a

clinical isolate of *Serratia marcescens*. *Antimicrob Agents Chemother* 2012; 56: 4945-4947.

55. Hamprecht A, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P. Detection of the carbapenemase GIM-1 in *Enterobacter cloacae* in Germany. *J Antimicrob Chemother* 2013; 68: 558-561.

56. Kaase M, Szabados F, Pfennigwerth N *et al*. Description of the metallo- β -lactamase GIM-1 in *Acinetobacter pittii*. *J Antimicrob Chemother* 2014; 69: 81-84.

57. Toleman MA, Simm AM, Murphy TA *et al*. Molecular characterization of SPM-1, a novel metallo- β -lactamase isolated in Latin America: report from the SENTRY antimicrobial surveillance programme. *J Antimicrob Chemother* 2002; 50: 673-679.

58. Lee K, Yum JH, Yong D *et al*. Novel acquired metallo- β -lactamase gene, *bla*_{SIM-1}, in a class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. *Antimicrob Agents Chemother* 2005; 49: 4485-4491.

59. Poirel L, Rodríguez-Martínez JM, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann P. Characterization of DIM-1, an integron-encoded metallo- β -lactamase from a *Pseudomonas stutzeri* clinical isolate in the Netherlands. *Antimicrob Agents Chemother* 2010; 54: 2420-2424.

60. El Salabi A, Borra PS, Toleman MA, Samuelsen Ø, Walsh TR. Genetic and biochemical characterization of a novel metallo-β-lactamase, TMB-1, from an *Achromobacter xylosoxidans* strain isolated in Tripoli, Libya. *Antimicrob Agents Chemother* 2012; 56: 2241-2245.
61. Yong D, Toleman MA, Bell J *et al.* Genetic and biochemical characterization of an acquired subgroup B3 metallo-β-lactamase gene, *bla*_{AIM-1}, and its unique genetic context in *Pseudomonas aeruginosa* from Australia. *Antimicrob Agents Chemother* 2012; 56: 6154-6159.
62. Yong D, Toleman MA, Giske CG *et al.* Characterization of a new metallo-β-lactamase gene, *bla*_{NDM-1}, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother* 2009; 53: 5046-5054.
63. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. *Trends Microbiol* 2011; 19: 588-595.
64. Dortet L, Poirel L, Nordmann P. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. *Biomed Res Int* 2014; 249856.
65. Williamson DA, Sidjabat HE, Freeman JT *et al.* Identification and molecular

characterisation of New Delhi metallo- β -lactamase-1 (NDM-1)- and NDM-6-producing *Enterobacteriaceae* from New Zealand hospitals. *Int J Antimicrob Agents* 2012; 39: 529-533.

66. Tada T, Miyoshi-Akiyama T, Dahal RK *et al.* NDM-8 metallo- β -lactamase in a multidrug-resistant *Escherichia coli* strain isolated in Nepal. *Antimicrob Agents Chemother* 2013; 57: 2394-2396.

67. Nordmann P, Boulanger AE, Poirel L. NDM-4 metallo- β -lactamase with increased carbapenemase activity from *Escherichia coli*. *Antimicrob Agents Chemother* 2012; 56: 2184-2186.

68. Cuzon G, Bonnin RA, Nordmann P. First identification of novel NDM carbapenemase, NDM-7, in *Escherichia coli* in France. *PLoS One* 2013; 8: e61322.

69. Gottig S, Hamprecht AG, Christ S, Kempf VA, Wichelhaus TA. Detection of NDM-7 in Germany, a new variant of the New Delhi metallo- β -lactamase with increased carbapenemase activity. *J Antimicrob Chemother* 2013; 68: 1737-1740.

70. Rahman M, Shukla SK, Prasad KN *et al.* Prevalence and molecular characterization of New Delhi metallo β -lactamases NDM-1, NDM-5, NDM-6, and NDM-7 in multidrug-resistant *Enterobacteriaceae* from India. *Int J Antimicrob Agents* 2014; in press.

71. Johnson AP, Woodford N. Global spread of antibiotic resistance; the example of New Delhi metallo- β -lactamase (NDM)- mediated carbapenem resistance type. *J Med Microbiol* 2013; 62: 499-513.
72. Poirel L, Dortet L, Bernabeu S, Nordmann P. Genetic features of *bla*_{NDM-1}-positive *Enterobacteriaceae*. *Antimicrob Agents Chemother* 2011; 55: 5403-5407.
73. Cornaglia G, Giamarellou H, Rossolini GM. Metallo- β -lactamases: a last frontier for β -lactams ? *Lancet Infect Dis* 2011; 11: 381-393.
74. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. *Lancet Infect Dis* 2011; 11: 355-362.
75. Kumarasamy KK, Toleman MA, Walsh TR *et al*. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 2010; 10: 597-602.
76. Perry JD, Naqvi SH, Mirza IA *et al*. Prevalence of faecal carriage of *Enterobacteriaceae* with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. *J Antimicrob Chemother* 2011; 66: 2288-2294.
77. Day KD, Salman M, Kazi B *et al*. Prevalence of NDM-1 carbapenemase in patients

with diarrhoea in Pakistan and evaluation of two chromogenic culture media. *J Applied Microbiol* 2013; 114:1810-1816.

78. Berrazeg M, Diene SM, Medjahed L *et al.* New Delhi metallo β -lactamase around the world; an eReview using google maps. *Euro Surveill* 2014; 19(20):pii=20809.

79. Halaby H, Reuland AE, Al Naiemi N *et al.* A case of New Delhi metallo- β -lactamase 1 (NDM-1)-producing *Klebsiella pneumoniae* with putative secondary transmission from the Balkan region in the Netherlands. *Antimicrob Agents Chemother* 2012; 56: 2790-2791.

80. Mazzariol A, Bosnjak Z, Ballarini P *et al.* NDM-1-producing *Klebsiella pneumoniae*, Croatia. *Emerg Infect Dis* 2012; 18: 532-534.

81. Zowawi HW, Balkhy HH, Walsh TR, Paterson DL. β -Lactamase production in key gram-negative pathogen isolates from the Arabian peninsula. *Clin Microbiol Rev* 2013; 26: 361-380.

82. Jamal W, Rotimi VO, Albert MJ, Khodakhast F, Udo EE, Poirel L. Emergence of nosocomial New Delhi metallo- β -lactamase-1 (NDM-1)-producing *Klebsiella pneumoniae* in patients admitted to a tertiary care hospital in Kuwait. *Int J Antimicrob Agents* 2012; 39: 183-184.

83. Khan A, Nordmann P. Spread of carbapenemase NDM-1 producers. The situation in India and what can be done. *Scand J Infect Dis* 2012; 44: 531-535.
84. Pasteran F, Albomoz E, Faccone D *et al.* Emergence of NDM-1 producing *Klebsiella pneumoniae* in Guatemala. *J Antimicrob Chemother* 2012; 67: 1795-1797.
85. Brink AJ, Coetzee J, Clay CG *et al.* Emergence of New Delhi metallo- β -lactamase (NDM-1) and *Klebsiella pneumoniae* carbapenemase (KPC-2) in South Africa. *J Clin Microbiol* 2012; 50: 525-527.
86. Shahcheraghi F, Nobari S, Rahmati GF *et al.* First report of New Delhi metallo- β -lactamase-1-producing *Klebsiella pneumoniae* in Iran. *Microb Drug Resist* 2013; 19: 30-36.
87. Qin S, Fu Y, Zhang Q *et al.* High incidence and endemic spread of NDM-1 positive *Enterobacteriaceae* in Henan province. *Antimicrob Agents Chemother* 2014; in press.
88. Poirel L, Hombrouck-Alet C, Freneaux C, Bernabeu S, Nordmann P. Global spread of New Delhi metallo- β -lactamase 1. *Lancet Infect Dis* 2010; 10: 832.
89. Poirel L, Savov E, Nazli A *et al.* Outbreak caused by NDM-1- and RmtB-producing *Escherichia coli* in Bulgaria. *Antimicrob Agents Chemother* 2014; 58: 2472-2474.
90. Poirel L, Yilmaz M, Istanbulu A *et al.* Spread of NDM-1-producing

Enterobacteriaceae in a neonatal intensive care unit in Istanbul, Turkey. *Antimicrob Agents Chemother* 2014; 58: 2929-2933.

91. Poirel L, Hervé V, Hombrouck-Alet C, Nordmann P. Long-term carriage of NDM-1 producing *Escherichia coli*. *J Antimicrob Chemother* 2011; 66: 2185-2186.

92. Nordmann P, Couard JP, Sansot D, Poirel L. Emergence of an autochthonous and community-acquired NDM-1-producing *Klebsiella pneumoniae* in Europe. *Clin Infect Dis* 2012; 54: 150-151.

93. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing *Enterobacteriaceae*. *Emerg Infect Dis* 2011; 17: 1791-1798.

94. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β -lactamases. *Antimicrob Agents Chemother* 2010; 54: 24-38.

95. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. *J Antimicrob Chemother* 2012; 67: 1597-1606.

96. Poirel L, Héritier C, Tolün V *et al.* Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2004; **48**: 15-22.

97. Carrër A, Poirel L, Eraksoy H *et al.* Spread of OXA-48-positive carbapenem-resistant *Klebsiella pneumoniae* isolates in Istanbul, Turkey. *Antimicrob Agents Chemother*

2008; **52**: 2950-2954.

98. Gülmez D, Woodford N, Palepou MF *et al.* Carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. *Int J Antimicrob Agents* 2008; **31**: 523-526.
99. Aktas Z, Bal Kayacan C, Schneider I *et al.* Carbapenem-hydrolyzing oxacillinase OXA-48 persists in *Klebsiella pneumoniae* in Istanbul, Turkey. *Chemotherapy* 2008; **54**: 101-106.
100. Pfeifer Y, Schlatterer K, Engelmann E *et al.* Emergence of OXA-48-type carbapenemase-producing *Enterobacteriaceae* in German hospitals. *Antimicrob Agents Chemother* 2012; **56**:2125-2128.
101. Potron A, Kalpoe J, Poirel L, Nordmann P. European dissemination of a single OXA-48-producing *Klebsiella pneumoniae* clone. *Clin Microbiol Infect* 2011; **17**: E24-26.
102. Dautzenberg MJ, Ossewaarde JM, de Kraker ME *et al.* Successful control of a hospital-wide outbreak of OXA-48 producing *Enterobacteriaceae* in the Netherlands, 2009 to 2011. *Euro Surveill* 2014; **19**(9).
103. Thomas CP, Moore LS, Elamin N *et al.* Early (2008-2010) hospital outbreak of

Klebsiella pneumoniae producing OXA-48 carbapenemase in the UK. *Int J Antimicrob Agents* 2013; 42: 531-536.

104. Dimou V, Dhanji H, Pike R, Livermore DM, Woodford N. Characterization of *Enterobacteriaceae* producing OXA-48-like carbapenemases in the UK. *J Antimicrob Chemother* 2012; 67: 1660-1665.

105. Potron A, Schrenzel J, Poirel L, Renzi G, Cherkaoui A, Nordmann P. Emergence of OXA-48-producing *Enterobacteriaceae* in Switzerland. *Int J Antimicrob Agents* 2012; 40: 563-564.

106. Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. *Antimicrob Agents Chemother* 2012; 56: 559-562.

107. Potron A, Poirel L, Nordmann P. Derepressed transfer properties leading to the efficient spread of the plasmid encoding carbapenemase OXA-48. *Antimicrob Agents Chemother* 2014; 58: 467-471.

108. Matar GM, Dandache I, Carrer A *et al.* Spread of OXA-48-mediated resistance to carbapenems in Lebanese *Klebsiella pneumoniae* and *Escherichia coli* that produce extended spectrum β -lactamase. *Ann Trop Med Parasitol* 2010; 104: 271-274.

109. Matar GM, Cuzon G, Araj F *et al.* Oxacillinase-mediated resistance to carbapenems in *Klebsiella pneumoniae* from Lebanon. *Clin Microbiol Infect* 2008; 14: 887-888.
110. Dortet L, Poirel L, Al Yaqoubi F, Nordmann P. NDM-1, OXA-48 and OXA-181 carbapenemase-producing *Enterobacteriaceae* in Sultanate of Oman. *Clin Microbiol Infect* 2012; 18: E144-148.
111. Al-Agamy MH, Shibl AM, Elkhizzi NA, Meunier D, Turton JF, Livermore DM. Persistence of *Klebsiella pneumoniae* clones with OXA-48 or NDM carbapenemases causing bacteraemias in a Riyadh hospital. *Diagn Microbiol Infect Dis* 2013; 76: 214-216.
112. Shibl A, Al-Agamy M, Memish Z, Senok A, Khader SA, Assiri A. The emergence of OXA-48- and NDM-1-positive *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. *Int J Infect Dis* 2013; 17: e1130-1133.
113. Zowawi HM, Sartor AL, Balkhy HH *et al.* Molecular characterization of carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* in the countries of the Gulf Cooperation Council: dominance of OXA-48 and NDM producers. *Antimicrob Agents Chemother* 2014; 58: 3085-3090.

114. Poirel L, Carbonnelle E, Bernabeu S, Gutmann L, Rotimi V, Nordmann P. Importation of OXA-48-producing *Klebsiella pneumoniae* from Kuwait. *J Antimicrob Chemother* 2012; 67: 2051-2052.
115. Cuzon G, Naas T, Lesenne A, Benhamou M, Nordmann P. Plasmid-mediated carbapenem-hydrolysing OXA-48 β -lactamase in *Klebsiella pneumoniae* from Tunisia. *Int J Antimicrob Agents* 2010; 36: 91-93.
116. Ktari S, Mnif B, Louati F *et al.* Spread of *Klebsiella pneumoniae* isolates producing OXA-48 β -lactamase in a Tunisian university hospital. *J Antimicrob Chemother* 2011; 66: 1644-1646.
117. Saïdani M, Hammami S, Kammoun A, Slim A, Boutiba-Ben Boubaker I. Emergence of carbapenem-resistant OXA-48 carbapenemase-producing *Enterobacteriaceae* in Tunisia. *J Med Microbiol* 2012; 61: 1746-1749.
118. Benouda A, Touzani O, Khairallah MT, Araj GF, Matar GM. First detection of oxacillinase-mediated resistance to carbapenems in *Klebsiella pneumoniae* from Morocco. *Ann Trop Med Parasitol* 2010; 104: 327-330.
119. Poirel L, Ros A, Carrër A *et al.* Cross-border transmission of OXA-48-producing *Enterobacter cloacae* from Morocco to France. *J Antimicrob Chemother*

2011; 66: 1181-1182.

120. Potron A, Kalpoe J, Poirel L, Nordmann P. European dissemination of a single OXA-48-producing *Klebsiella pneumoniae* clone. *Clin Microbiol Infect* 2011; 17: E24-26.
121. Hays C, Benouda A, Poirel L, Elouennass M, Nordmann P. Nosocomial occurrence of OXA-48-producing enterobacterial isolates in a Moroccan hospital. *Int J Antimicrob Agents* 2012; 39: 545-547.
122. Girlich D, Bouihat N, Poirel L, Benouda A, Nordmann P. High rate of faecal carriage of extended-spectrum β -lactamase and OXA-48 carbapenemase-producing *Enterobacteriaceae* at a university hospital in Morocco. *Clin Microbiol Infect* 2014; 20: 350-354.
123. Poirel L, Abdelaziz MO, Bernabeu S, Nordmann P. Occurrence of OXA-48 and VIM-1 carbapenemase-producing *Enterobacteriaceae* in Egypt. *Int J Antimicrob Agents* 2013; 41: 90-91.
124. Pirš M, Andlovic A, Cerar T *et al.* A case of OXA-48 carbapenemase-producing *Klebsiella pneumoniae* in a patient transferred to Slovenia from Libya, November 2011. *Euro Surveill* 2011; 16: 20042.

125. Kocsis E, Savio C, Piccoli M, Cornaglia G, Mazzariol A. *Klebsiella pneumoniae* harbouring OXA-48 carbapenemase in a Libyan refugee in Italy. *Clin Microbiol Infect* 2013; 19: E409-411.
126. Seiffert SN, Perreten V, Johannes S, Droz S, Bodmer T, Endimiani A. OXA-48 carbapenemase-producing *Salmonella enterica* serovar Kentucky isolate of sequence type 198 in a patient transferred from Libya to Switzerland. *Antimicrob Agents Chemother* 2014; 58: 2446-2449.
127. Agabou A, Pantel A, Ouchenane Z *et al.* First description of OXA-48-producing *Escherichia coli* and the pandemic clone ST131 from patients hospitalised at a military hospital in Algeria. *Eur J Clin Microbiol Infect Dis* 2014; in press.
128. Mocquet O, Bouchiat C, Kinana A *et al.* Class D OXA-48 carbapenemase in multidrug-resistant enterobacteria, Senegal. *Emerg Infect Dis* 2011; 17: 143-4.
129. Brink AJ, Coetzee J, Corcoran C *et al.* Emergence of OXA-48 and OXA-181 carbapenemases among *Enterobacteriaceae* in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. *J Clin Microbiol* 2013; 51: 369-372.
130. Adler A, Shklyar M, Schwaber MJ *et al.* Introduction of OXA-48-producing

Enterobacteriaceae to Israeli hospitals by medical tourism. *J Antimicrob Chemother* 2011; 66: 2763-2766.

131. Potron A, Nordmann P, Poirel L. Characterization of OXA-204, a carbapenem-hydrolyzing class D β -lactamase from *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2013; 57: 633-636.

132. Potron A, Nordmann P, Lafeuille E, Al Maskari Z, Al Rashdi F, Poirel L. Characterization of OXA-181, a carbapenem-hydrolyzing class D β -lactamase from *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2011; 55: 4896-4899.

133. Samuelsen O, Naseer U, Karah N *et al*. Identification of *Enterobacteriaceae* isolates with OXA-48 and coproduction of OXA-181 and NDM-1 in Norway. *J Antimicrob Chemother* 2013; 68: 1682-1685.

134. Potron A, Rondinaud E, Poirel L *et al*. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β -lactamase from *Enterobacteriaceae*. *Int J Antimicrob Agents* 2013; 41: 325-329.

135. Doi Y, O'Hara JA, Lando JF *et al*. Co-production of NDM-1 and OXA-232 by *Klebsiella pneumoniae*. *Emerg Infect Dis* 2014; 20: 163-165.

136. Poirel L, Castanheira M, Carrer A *et al*. OXA-163, an OXA-48-related class D

β -lactamase with extended activity toward expanded-spectrum cephalosporins.

Antimicrob Agents Chemother 2011; 55: 2546-2551.

137. Abdelaziz MO, Bonura C, Aleo A, El-Domany RA, Fasciana T, Mammina C.

OXA-163-producing *Klebsiella pneumoniae* in Cairo, Egypt, in 2009 and 2010. *J Clin*

Microbiol 2012; 50: 2489-2491.

138. Gomez S, Pasteran F, Faccone D *et al.* Inpatient emergence of OXA-247: a

novel carbapenemase found in a patient previously infected with OXA-163-producing

Klebsiella pneumoniae. *Clin Microbiol Infect* 2013; 19: E233-235.

Figure 1. KPC producers

- Unknown distribution of KPC producers
- Sporadic spread of KPC producers
- Outbreaks du to KPC producers
- Endemicity of KPC producers




Figure 2. NDM producers

- Unknown distribution of NDM producers
- Sporadic spread of NDM producers
- Outbreaks du to NDM producers
- Endemicity of NDM producers

